APN - Aspen Pharmacare Holdings - Official Statement Regarding the Alleged

APN - Aspen Pharmacare Holdings - Official Statement Regarding the Alleged      
    Purchase Transactions Entered into Between Aspen and Frankel Chemicals for  
    the Purchase by Aspen from Frankel Chemicals of Raw Materials for the       
Manufacture of Anti-Retrovials                                              
ASPEN PHARMACARE HOLDINGS LIMITED                                               
(Incorporated in the Republic of South Africa)                                  
Registration number 1985/0002935/06                                             
Share code:  APN                                                                
ISIN:  ZAE000066692                                                             
OFFICIAL STATEMENT REGARDING THE ALLEGED PURCHASE TRANSACTIONS ENTERED INTO     
BETWEEN ASPEN AND FRANKEL CHEMICALS FOR THE PURCHASE BY ASPEN FROM FRANKEL      
CHEMICALS OF RAW MATERIALS FOR THE MANUFACTURE OF ANTI-RETROVIALS               
ASPEN PHARMACARE HOLDINGS LIMITED AND ITS AFFILIATES ("Aspen") AND FRANKEL      
CHEMICALS ("Frankel")                                                           
It has come to the attention of Aspen that information allegedly pertaining to  
the business relationship between Frankel and Aspen has been provided to the    
international investment community and the general public. Aspen hereby wishes  
to clarify that the alleged purchases and related amounts owing are invalid and 
have arisen as a result of the falsification of documents.                      
The allegations are currently sub-judicae. Aspen will co-operate, without       
restriction, with all statutory investigating authorities and comply with all   
legal requirements relating to this matter.                                     
Frankel have alleged that:                                                      
(i) "Over the past five years, Frankel Chemicals has been awarded the contract  
to procure Anti-Retroviral ("ARV") ingredients for Aspen Pharmaceuticals Ltd in 
South Africa to combat the spread of HIV/AIDS. The contract was awarded based on
the good merits and relations Frankel has with this customer"*                  
(ii) Aspen is indebted to Frankel in the amount of R700 million;                
(iii) Mr Stephen Saad, the Chief Executive Officer of Aspen, has verbally       
confirmed "payment terms" with Frankel for the payment of the aforesaid sum of  
R700 million.                                                                   
Aspen hereby confirms the following facts:                                      
(i)  Aspen currently purchases selected raw materials directly from Frankel;    
(ii) whilst Frankel is listed as an agent of Aspen for the supply of certain    
other chemicals, Aspen deals directly with the suppliers thereof on a direct    
indent basis;                                                                   
(iii) Aspen has transacted with Frankel and Frankel International, but has not  
undertaken business with any of the following entities (which purportedly form  
part of the Frankel Group), namely:                                             
- Eurochemicals Pty Ltd                                                         
- Frankel SA                                                                    
- Frankel Enterprises                                                           
- Frankel Asset Management                                                      
- Abated Investments; and                                                       
- Bartan Group (Australia).                                                     
(iv) As at the date of this letter there are no monies due to or owing to       
Frankel or payable by Aspen to Frankel, or any of its affiliates, for the       
alleged purchases of ARV materials.                                             
(v) Aspen purchases all of its Active Pharmaceutical Ingredients, which are used
for the manufacture of ARV products, from other third party suppliers.          
(vi) Aspen is aware of the existence of documents representing to be purchase   
orders and other correspondence between Aspen and Frankel which were neither    
prepared nor authorized by Aspen. These documents have been fraudulently        
prepared using forged purchase order templates and forged signatures,           
representing Aspen personnel.                                                   
Should you have specific queries on this matter, please contact Mr. Pieter van  
der Sandt, Legal Counsel for Aspen on (011) 239 6522.                           
Issued by:                                                                      
Roshni Gajjar, Investor Relations Manager, (031) 580 8649                       
On Behalf of:                                                                   
Stephen Saad: Group Chief Executive; and                                        
Gus Attridge: Deputy Group Chief Executive                                      
12 JUNE 2009                                                                    
Sponsor: Investec Bank Limited                                                  
Date: 12/06/2009 16:35:02 Supplied by www.sharenet.co.za                     
Produced by the JSE SENS Department.                  
The SENS service is an information dissemination service administered by the    
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or            
implicitly, represent, warrant or in any way guarantee the truth, accuracy or   
completeness of the information published on SENS. The JSE, their officers,     
employees and agents accept no liability for (or in respect of) any direct,     
indirect, incidental or consequential loss or damage of any kind or nature,     
howsoever arising, from the use of SENS or the use of, or reliance on,          
information disseminated through SENS.